How much cash does Opus Genetics generate?

Opus Genetics (IRD) generated -$39.0M in operating cash flow over the trailing twelve months.

Where does Opus Genetics's cash flow data come from?

Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Opus Genetics IRD Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$49.59M+13.8%	-$57.53M-476%	-$9.99M-156%	$17.89M+132%
Depreciation and amortization	$53K+430%	$10K+66.7%	$6K+50.0%	$4K0.0%
Stock-based compensation	$3.4M+1.1%	$3.36M-4.2%	$3.51M+94.2%	$1.81M-5.6%
Change in accounts receivable	——	——	-$372K-129%	$1.3M—
Change in accounts payable	$7K-96.8%	$220K—	——	-$515K—
Change in accrued liabilities	-$3.5M-160%	$5.84M—	——	——
Change in other assets	——	——	——	$139K+209%
Net gains (losses) on investments	——	-$13K—	——	-$170K-143%
Net cash from operating activities	-$35.25M-37.8%	-$25.58M—	——	$14.31M+174%
Acquisitions, net of cash acquired	$0-100%	$1.21M—	$0—	$0-100%
Net cash from investing activities	$0-100%	$1.21M—	$0—	$0+100%
Proceeds from issuance of common stock	$5.81M+29.1%	$4.5M-51.3%	$9.23M—	——
Proceeds from issuance of preferred stock	——	——	——	——
Net cash from financing activities	$50.02M+1,072%	$4.27M-52.5%	$8.98M+136%	$3.8M-86.2%
Net increase (decrease) in cash	——	-$20.18M—	——	$18.1M—
Interest paid	$0—	$0—	$0—	——
Income taxes paid	$0—	$0-100%	$344K—	$0—
Asset Acquisition Gain Loss On Acquisition Of Business	$0-100%	$2.45M—	$0—	——
Depreciation	$53K+430%	$10K+66.7%	$6K+50.0%	$4K0.0%
Gain (Loss) on Derivative Instruments, Net, Pretax	-$11.52M-16,093%	$72K-10.0%	$80K—	$0+100%
Accrued expenses and other liabilities	-$3.5M-160%	$5.84M—	——	——
Increase (Decrease) in Contract Assets and Unbilled Receivables	——	$802K+137%	-$2.15M—	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	$139K+209%
Non Cash Share Issuances	$57K—	$0—	——	——
Research And Development Expense Including Acquired In Process Cost	$0-100%	$28M—	$0—	——
Warrant financing costs	——	$0—	——	——
Payments Of Stock Issuance Costs	$2.3M+892%	$232K-16.5%	$278K+112%	$131K-91.3%
Proceeds From Issuance In Connection With Registered Direct Offering	$23M—	$0—	——	——
Proceeds from issuance of common stock and pre-funded warrants in connection with the March 2025 offering and March 2025 private placement	——	$0—	——	——
Proceeds from issuance of warrants in connection with the March 2025 offering and March 2025 private placement	——	$0—	——	——
Share Repurchases for Payment of Employee Taxes	——	——	——	——
Interest Expense, Nonoperating	$129K—	——	——	——
Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1	$0-100%	$955K—	$0—	——
Reclassification Of Warrant Liabilities To Equity Upon Exercise	$1.05M—	$0—	——	——
Unrealized Gain (Loss) on Investments	——	-$13K—	——	-$170K-143%
Income Taxes Paid, Net	$0—	$0-100%	$344K—	$0—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Opus Genetics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Opus Genetics generate?: Opus Genetics (IRD) generated -$39.0M in operating cash flow over the trailing twelve months.
Where does Opus Genetics's cash flow data come from?: Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.